ZeroStack Corp., formerly Flora Growth, files its annual report describing a major pivot from legacy hemp and cannabis into a combination of decentralized AI-focused digital asset treasury management and global pharmaceutical distribution through its German unit Phatebo.
The company is building a treasury concentrated in 0G Tokens and other cryptocurrencies, funded by multiple 2025 private placements that raised about $14.6M in cash plus significant token consideration, and by borrowing 50,000,000 0G Tokens under a convertible note with related party Zero Gravity Labs. It also issued and settled a Solana-denominated convertible note and entered a large token-funded pre-funded warrant deal.
ZeroStack sold its legacy hemp and cannabis subsidiaries in 2025 to extinguish promissory note obligations and now focuses on AI-linked digital assets and pharmaceutical wholesaling. Despite this repositioning, it remains early stage and deeply loss-making, with a $119.7M net loss in 2025 and an accumulated deficit of $277.8M. As of February 23, 2026, it had 2,430,808 common shares outstanding and a small workforce of 21 employees.
ZeroStack Corp., formerly Flora Growth, files its annual report describing a major pivot from legacy hemp and cannabis into a combination of decentralized AI-focused digital asset treasury management and global pharmaceutical distribution through its German unit Phatebo.
The company is building a treasury concentrated in 0G Tokens and other cryptocurrencies, funded by multiple 2025 private placements that raised about $14.6M in cash plus significant token consideration, and by borrowing 50,000,000 0G Tokens under a convertible note with related party Zero Gravity Labs. It also issued and settled a Solana-denominated convertible note and entered a large token-funded pre-funded warrant deal.
ZeroStack sold its legacy hemp and cannabis subsidiaries in 2025 to extinguish promissory note obligations and now focuses on AI-linked digital assets and pharmaceutical wholesaling. Despite this repositioning, it remains early stage and deeply loss-making, with a $119.7M net loss in 2025 and an accumulated deficit of $277.8M. As of February 23, 2026, it had 2,430,808 common shares outstanding and a small workforce of 21 employees.